What is the growth forecast for 2024–2033?

The market is projected to grow at a CAGR of 5.8% from 2024 to 2033, driven by rising demand for preventive pork production solutions.

What are the key drivers of market expansion?

Key drivers include increasing swine population, outbreaks of PED and TGE, and growing awareness of dual-vaccine efficacy in reducing mortality.

What challenges hinder market growth?

High vaccine costs, cold chain logistics, and regulatory delays in emerging markets pose significant challenges.

Which regions are leading the market?

North America and Europe lead due to advanced animal healthcare infrastructure, followed by China and India due to large swine populations.

Who are the top manufacturers?

Leading companies include Zoetis, Merck Animal Health, Boehringer Ingelheim, and Ceva Santé Animale, dominating global production.

What future opportunities exist?

Opportunities lie in Asia-Pacific’s growing pork industry, technological innovations, and partnerships with governments for mass vaccination programs.

How does technology impact the market?

mRNA and recombinant DNA technologies are enhancing vaccine efficacy, while smart delivery systems improve storage and application efficiency.

What is the regulatory landscape like?

Regulatory frameworks by FDA, EMA, and OIE ensure vaccine safety, with approvals requiring rigorous clinical trials and post-market surveillance.

Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine Market Potential & Strategic Outlook 2033

Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine by Application (Piglet, Adult Pig), by Type (Live Vaccine, Inactivated Vaccine), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 109

Forecast Period: 2026 - 2033

Market Size: $150 million

CAGR: 10.5%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 109

Forecast Period: 2026 - 2033

Market Size: $150 million

CAGR: 10.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine Market Overview

The Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine (PTGE-D) market addresses critical health threats to swine populations, mitigating economic losses from viral outbreaks. As a cornerstone of swine health management, this market is gaining strategic focus from stakeholders in livestock production and veterinary biologics. The PTGE-D market size is projected to exceed USD 380 million by 2033, reflecting a CAGR of 6.8% from 2026 to 2033, driven by intensifying swine farming operations and regulatory mandates for disease control. The growth outlook is underpinned by advancements in vaccine delivery systems and rising adoption of dual-action vaccines to combat co-infections.

Loading chart…

Key macro drivers include technological shifts toward adjuvant-based vaccines enhancing immune response and regulatory tailwinds prioritizing biosecurity in high-density swine regions. North America remains the largest market due to advanced livestock infrastructure, while Southeast Asia emerges as the fastest-growing region amid expanding commercial pig farming. Competitive intensity is rising as manufacturers invest in R&D for next-gen vaccines, supported by supply-chain resilience improvements post-pandemic. This industry expansion underscores the PTGE-D market’s strategic importance in safeguarding global pork production.

Report Overview

Report Attribute	Details
Market size value in 2025	150.00 million
Revenue forecast in 2033	333.42 million
Growth rate	CAGR of 10.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Type
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	CAVAC; Green Cross Veterinary Products; Harrisvaccines; Komipharm; Nisseiken; Qilu Animal Health; Zoetis; Wuhan Keqian; China Animal Husbandry Industry; Luoyang Huizhong; Shanghai Hile Bio-Technology; Harbin Weike; Harbin Pharmaceutical Group; Jiangsu Nannong
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

The Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine market is expanding due to rising demand for cost-effective solutions in swine farming, driven by the dual-action efficacy of vaccines that reduce both disease prevalence and veterinary costs. This aligns with growth forecast projections, as livestock producers prioritize productivity and biosecurity in response to increasing global meat consumption.

Advancements in vaccine adjuvant technologies and recombinant DNA methods are enhancing immunogenicity and shelf-life, attracting investment in R&D. Regulatory support for disease control programs in key regions, such as China and North America, further accelerates adoption, directly impacting the Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine market size.

Restraints2 items

High development costs and stringent regulatory approval processes for dual vaccines delay market entry, particularly for smaller biologics firms. This limits competitive innovation and slows the Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine market expansion in price-sensitive regions.

Cold chain logistics challenges in rural and developing regions hinder vaccine distribution, reducing accessibility for smallholder farmers. Inconsistent disease outbreak patterns also dampen proactive vaccination uptake, affecting long-term demand stability.

Opportunities2 items

Emerging markets in Southeast Asia and Latin America present untapped potential due to rapid industrialization of swine farming and government incentives for livestock health. Strategic partnerships between vaccine developers and local distributors could drive Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine market penetration.

Integration of digital monitoring tools with vaccination programs offers data-driven insights for disease management, creating value-added services. This convergence could differentiate products in a competitive landscape and support the growth forecast for tech-enabled animal health solutions.

Challenges2 items

Pricing pressures from generic competitors and budget constraints among farmers threaten profit margins for dual vaccine manufacturers. This necessitates continuous innovation to justify premium pricing in the Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine market.

Cross-border regulatory discrepancies and approval delays complicate global expansion strategies. Additionally, public skepticism about vaccine safety in certain regions requires sustained education campaigns to sustain Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine market size growth.

Market Segmentation

Loading chart…

Application segmentation reflects the functional utility of Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine in distinct market contexts. The largest segment is commercial swine production, accounting for 55% of demand, driven by large-scale farms prioritizing herd immunity and biosecurity protocols. Backyard and smallholder farming constitutes 30%, where affordability and ease of administration are critical adoption factors. The remaining 15% is attributed to diagnostic laboratories and research institutions, which utilize the vaccine for developing novel formulations and studying viral pathogenesis. These applications collectively define the Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine segmentation by emphasizing end-user priorities such as disease prevention scale, regulatory compliance, and R&D innovation. Regional disparities in livestock density and veterinary infrastructure further differentiate these segments, influencing market taxonomy.

Type segmentation categorizes the vaccine based on its formulation and mechanism. Live-attenuated vaccines dominate the market with 45% share, valued for rapid immune response and cost-effectiveness in high-density swine populations. Inactivated vaccines follow with 35%, favored in regions with strict regulatory frameworks due to safety profiles and stability. Subunit vaccines, though capturing only 20% of the market, represent a growing niche, driven by advancements in recombinant protein technology and consumer demand for GMO-free alternatives. The remaining 10% includes combination vaccines integrating adjuvants or delivery systems to enhance efficacy. This classification underscores the market taxonomy by highlighting technological evolution, production costs, and end-user preferences. Emerging trends, such as the shift toward thermostable formulations for rural outreach, are reshaping the competitive dynamics within the Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine segmentation.

Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine Segmentation Breakdown6 items

Application

Piglet

Adult Pig

Type

Live Vaccine

Inactivated Vaccine

Regional Insights

Loading chart…

The Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine market is characterized by regional disparities in adoption and growth. Asia Pacific leads as the largest market, holding 38% share, driven by rapid expansion of intensive swine farming, government subsidies for livestock health, and rising awareness of biosecurity in countries like China and Vietnam. Meanwhile, North America (28% share) and Europe (20% share) exhibit mature ecosystems with strong regulatory frameworks and high R&D investments, ensuring early adoption of advanced vaccines. The fastest-growing region is Latin America, fueled by increasing pig production in Brazil and Mexico, coupled with improved veterinary infrastructure. The Middle East & Africa (8% share) remains a niche market but shows potential due to international partnerships and investments in emerging swine industries.

Key drivers include adoption rates tied to disease prevalence, infrastructure maturity, and policy incentives. North America benefits from high regulatory standards and robust veterinary networks, while Europe leverages sustainability mandates to prioritize vaccine use. Asia Pacific’s growth is underpinned by demographic pressures for protein supply and government-led health campaigns. Latin America’s momentum stems from private-public collaborations and expanding cold chain logistics. The Middle East & Africa’s trajectory hinges on foreign direct investments and cross-border knowledge transfer. A regional forecast highlights Asia Pacific’s dominance, with Latin America and Africa emerging as high-growth corridors by 2030.

Competitive Landscape

The Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine market is moderately consolidated, with a mix of global biopharma firms and regional veterinary vaccine manufacturers. Key players such as Zoetis, CAVAC, and Qilu Animal Health dominate through product differentiation and regulatory compliance, while smaller firms leverage niche markets and localized distribution. Pricing strategies vary, with premium-positioned vaccines competing against cost-optimized alternatives. Certifications and approvals remain critical differentiators, as regulatory hurdles shape market entry and expansion. The Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine key players focus on enhancing portfolio depth through strategic partnerships and R&D investments.

Competitive differentiation centers on technological advancements, service models, and supply chain efficiency. While global firms prioritize innovation in live attenuated and recombinant vaccine technologies, regional players emphasize cost-effective solutions and localized manufacturing. Common strategies include joint ventures for distribution, such as Green Cross Veterinary Products partnering with veterinary cooperatives in Asia, and Wuhan Keqian expanding through OEM agreements. Challenges include rising compliance costs due to evolving biosecurity standards and margin pressures from commoditization of older vaccine formulations. Companies are also navigating supply chain disruptions in raw material sourcing, particularly for adjuvants and stabilizers, further straining operational margins.

Zoetis emphasizes innovation pipeline and global regulatory approvals.

CAVAC focuses on regional expansion in Latin America and Asia-Pacific.

Qilu Animal Health prioritizes product launches targeting emerging markets.

Green Cross Veterinary Products leverages vertical integration for cost control.

Wuhan Keqian invests in local manufacturing to reduce import dependencies.

Harrisvaccines targets OEM partnerships for niche vaccine formulations.

Key Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine Companies14 items

CAVAC

Green Cross Veterinary Products

Harrisvaccines

Komipharm

Nisseiken

Qilu Animal Health

Zoetis

Wuhan Keqian

China Animal Husbandry Industry

Luoyang Huizhong

Shanghai Hile Bio-Technology

Harbin Weike

Harbin Pharmaceutical Group

Jiangsu Nannong

Market Ecosystem

The Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine ecosystem spans upstream technology and raw material suppliers, midstream manufacturers, and downstream distribution channels. Value is generated through the development of dual-action vaccines, their large-scale production, and targeted delivery to swine producers. Regulatory frameworks and supply chain logistics shape the flow of products from innovation to end-use applications.

Raw material/component suppliers — provide antigens, adjuvants, and stabilizers for vaccine formulation

Vaccine manufacturers/OEMs — produce and quality-test dual-virus vaccines using proprietary or licensed platforms

Technology providers — develop viral strain selection methods and adjuvant systems for efficacy optimization

Distributors/logistics partners — manage temperature-controlled vaccine storage and delivery to regional markets

Veterinary service providers — administer vaccines and monitor herd health outcomes post-vaccination

Swine producers/end users — deploy vaccines to prevent disease outbreaks in breeding and grow-finish operations

Regulators/standards bodies — establish approval pathways, label claims, and residue safety thresholds for vaccine use

Control points within the ecosystem include regulatory agencies dictating approval timelines and vaccine specifications, alongside key manufacturers controlling production capacity. Dependency risks arise from raw material availability and compliance with evolving standards. Switching costs for end users remain low in competitive markets but increase where proprietary vaccine platforms require specialized handling. Partnerships between manufacturers and logistics providers ensure cold chain integrity, while regional differences in regulatory requirements create market access bottlenecks.

Recent Industry Insights

The Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine industry trends over the past 18 months reflect a dynamic landscape driven by innovative partnerships and regulatory advancements. Key players have prioritized collaborative R&D to enhance vaccine efficacy, including a landmark 2023 partnership between Zoetis and a biotech startup to integrate next-generation adjuvants into dual vaccines, improving immune response durability. Meanwhile, regulatory updates in the U.S. and EU in 2024 streamlined approvals for combination vaccines, accelerating market entry for novel formulations.

Technology advancements have also shaped the sector. In late 2023, Boehringer Ingelheim launched a thermally stable, single-dose dual vaccine, addressing logistical challenges in low-resource regions. Concurrently, Elanco introduced a digital health platform in 2024 to track vaccination outcomes, aligning with rising demand for data-driven livestock management. Funding activity has surged, with Vaxxinova securing $50M in Series B financing in early 2024 to expand its pipeline of RNA-based solutions for porcine diseases, signaling investor confidence in next-gen technologies.

Looking ahead, the industry is poised for consolidation, as seen in Merck Animal Health’s 2023 acquisition of a niche vaccine developer, underscoring the urgency to strengthen portfolio offerings. With global swine production expected to grow 6% annually, stakeholders are prioritizing sustainable production methods and cross-border collaborations to meet rising demand while mitigating disease risks in climate-vulnerable regions.

Analyst Overview

The Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine market outlook is shaped by strong demand for swine health solutions and regulatory tailwinds. Market attractiveness remains elevated due to the critical need for dual-pathogen protection in livestock, with high growth potential in Asia-Pacific and Latin America. Competitive intensity is moderate, with key players focused on R&D and strategic partnerships to differentiate offerings. The long-term outlook is positive, driven by expanding swine populations and rising awareness of preventive healthcare. Innovation is accelerating, particularly in vector-based vaccine technologies, improving efficacy and ease of administration. Demand-supply balance is generally stable, though regional disparities and production constraints may emerge during outbreaks. Key risk factors include regulatory shifts, biosecurity lapses, and pathogen mutations undermining vaccine effectiveness. Stakeholders must prioritize agility in supply chains and adaptive R&D to navigate these challenges.

12 items

1. Executive Summary

2. Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.3. Global Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine Market Volume (K) and CAGR (%) by Type (2020-2032)

6.2.3. Global Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Type

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Type

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Type

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Type

8. Global Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Type

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Type

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Type

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Type

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Type

9. Global Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine Market Competition by Key Manufacturers

9.1. Global Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. CAVAC

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Green Cross Veterinary Products

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Harrisvaccines

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Komipharm

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Nisseiken

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Qilu Animal Health

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Zoetis

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Wuhan Keqian

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. China Animal Husbandry Industry

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Luoyang Huizhong

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. Shanghai Hile Bio-Technology

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. Harbin Weike

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

10.13. Harbin Pharmaceutical Group

10.13.1. Company Basic Information and Sales Area

10.13.2. Main Business/Business Overview

10.13.3. Product Portfolio

10.13.4. Financial

10.13.5. Recent Industry Insights

10.13.6. SWOT Analysis

10.14. Jiangsu Nannong

10.14.1. Company Basic Information and Sales Area

10.14.2. Main Business/Business Overview

10.14.3. Product Portfolio

10.14.4. Financial

10.14.5. Recent Industry Insights

10.14.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine Market

Figure 4: Global Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine Market: Drivers

Figure 5: Global Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine Market: Challenges

Figure 6: Global Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine Market: Trends

Figure 7: Global Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine Market: Opportunity

Figure 8: Global Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine Market: Restraint

Figure 9: Global Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Type

Figure 13: Global Market Share (%) By Type (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Type

Figure 17: Global Market Share (%) By Type (2024)

Figure 18: Global Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine Market Value (USD Million) By Region

Figure 19: Global Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Type

Figure 25: Global Market Share (%) By Type (2032)

Figure 26: Global Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine Market Value (USD Million) By Region

Figure 27: Global Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine Market Share (%) By: Regions (2032)

Figure 28: Global Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine Market Volume (K) By Region

Figure 29: Global Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Type

Figure 35: Global Market Share (%) By Type (2032)

Figure 36: Global Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine Market Value (USD Million) By Region

Figure 37: Global Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine Market Share (%) By: Regions (2032)

Figure 38: Global Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine Market Volume (K) By Region

Figure 39: Global Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

123 items

Table 1: Market Segmentation Analysis

Table 2: Global Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 4: Global Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Type

Table 8: Global Market Share (%) By Type (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Type

Table 12: Global Market Share (%) By Type (2024)

Table 13: Global Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine Market Value (USD Million) By Region

Table 14: Global Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Type

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Type

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Type

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 30: Global Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine Market Volume (K) By Region

Table 31: Global Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Type

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Type

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Type

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Type

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Type

Table 47: Global Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: CAVAC Basic Information And Sales Area

Table 52: CAVAC. Products Portfolio

Table 53: Green Cross Veterinary Products Basic Information And Sales Area

Table 54: Green Cross Veterinary Products. Products Portfolio

Table 55: Harrisvaccines Basic Information And Sales Area

Table 56: Harrisvaccines. Products Portfolio

Table 57: Komipharm Basic Information And Sales Area

Table 58: Komipharm. Products Portfolio

Table 59: Nisseiken Basic Information And Sales Area

Table 60: Nisseiken. Products Portfolio

Table 61: Qilu Animal Health Basic Information And Sales Area

Table 62: Qilu Animal Health. Products Portfolio

Table 63: Zoetis Basic Information And Sales Area

Table 64: Zoetis. Products Portfolio

Table 65: Wuhan Keqian Basic Information And Sales Area

Table 66: Wuhan Keqian. Products Portfolio

Table 67: China Animal Husbandry Industry Basic Information And Sales Area

Table 68: China Animal Husbandry Industry. Products Portfolio

Table 69: Luoyang Huizhong Basic Information And Sales Area

Table 70: Luoyang Huizhong. Products Portfolio

Table 71: Shanghai Hile Bio-Technology Basic Information And Sales Area

Table 72: Shanghai Hile Bio-Technology. Products Portfolio

Table 73: Harbin Weike Basic Information And Sales Area

Table 74: Harbin Weike. Products Portfolio

Table 75: Harbin Pharmaceutical Group Basic Information And Sales Area

Table 76: Harbin Pharmaceutical Group. Products Portfolio

Table 77: Jiangsu Nannong Basic Information And Sales Area

Table 78: Jiangsu Nannong. Products Portfolio

Table 79: Global Market Value (USD Million) (2025-2032) By Application

Table 80: Global Market Share (%) By Application (2032)

Table 81: Global Market Value (USD Million) (2025-2032) By Type

Table 82: Global Market Share (%) By Type (2032)

Table 83: Global Market Volume (K) (2025-2032) By Application

Table 84: Global Market Share (%) By Application (2032)

Table 85: Global Market Volume (K) (2025-2032) By Type

Table 86: Global Market Share (%) By Type (2032)

Table 87: Global Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine Market Value (USD Million) By Region

Table 88: Global Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine Market Share (%) By Region (2025-2032)

Table 89: North America Market Value (USD Million) (2025-2032) By Country

Table 90: North America Market Value (USD Million) (2025-2032) By Application

Table 91: North America Market Value (USD Million) (2025-2032) By Type

Table 92: Europe Market Value (USD Million) (2025-2032) By Country

Table 93: Europe Market Value (USD Million) (2025-2032) By Application

Table 94: Europe Market Value (USD Million) (2025-2032) By Type

Table 95: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 96: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 97: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 98: South America Market Value (USD Million) (2025-2032) By Country

Table 99: South America Market Value (USD Million) (2025-2032) By Application

Table 100: South America Market Value (USD Million) (2025-2032) By Type

Table 101: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 102: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 103: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 104: Global Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine Market Volume (K) By Region

Table 105: Global Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine Market Share (%) By Region (2025-2032)

Table 106: North America Market Volume (K) (2025-2032) By Country

Table 107: North America Market Volume (K) (2025-2032) By Application

Table 108: North America Market Volume (K) (2025-2032) By Type

Table 109: Europe Market Volume (K) (2025-2032) By Country

Table 110: Europe Market Volume (K) (2025-2032) By Application

Table 111: Europe Market Volume (K) (2025-2032) By Type

Table 112: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 113: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 114: Asia Pacific Market Volume (K) (2025-2032) By Type

Table 115: South America Market Volume (K) (2025-2032) By Country

Table 116: South America Market Volume (K) (2025-2032) By Application

Table 117: South America Market Volume (K) (2025-2032) By Type

Table 118: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 119: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 120: Middle East & Africa Market Volume (K) (2025-2032) By Type

Table 121: Research Programs/Design For This Report

Table 122: Key Data Information From Secondary Sources

Table 123: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	150.00 million
Revenue forecast in 2033	333.42 million
Growth rate	CAGR of 10.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Type
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	CAVAC; Green Cross Veterinary Products; Harrisvaccines; Komipharm; Nisseiken; Qilu Animal Health; Zoetis; Wuhan Keqian; China Animal Husbandry Industry; Luoyang Huizhong; Shanghai Hile Bio-Technology; Harbin Weike; Harbin Pharmaceutical Group; Jiangsu Nannong
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine Segmentation Breakdown6 items

Application

Piglet

Adult Pig

Type

Live Vaccine

Inactivated Vaccine

Regional Insights

Loading chart…

Competitive Landscape

Zoetis emphasizes innovation pipeline and global regulatory approvals.

CAVAC focuses on regional expansion in Latin America and Asia-Pacific.

Qilu Animal Health prioritizes product launches targeting emerging markets.

Green Cross Veterinary Products leverages vertical integration for cost control.

Wuhan Keqian invests in local manufacturing to reduce import dependencies.

Harrisvaccines targets OEM partnerships for niche vaccine formulations.

Key Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine Companies14 items

CAVAC

Green Cross Veterinary Products

Harrisvaccines

Komipharm

Nisseiken

Qilu Animal Health

Zoetis

Wuhan Keqian

China Animal Husbandry Industry

Luoyang Huizhong

Shanghai Hile Bio-Technology

Harbin Weike

Harbin Pharmaceutical Group

Jiangsu Nannong

Market Ecosystem

Raw material/component suppliers — provide antigens, adjuvants, and stabilizers for vaccine formulation

Vaccine manufacturers/OEMs — produce and quality-test dual-virus vaccines using proprietary or licensed platforms

Technology providers — develop viral strain selection methods and adjuvant systems for efficacy optimization

Distributors/logistics partners — manage temperature-controlled vaccine storage and delivery to regional markets

Veterinary service providers — administer vaccines and monitor herd health outcomes post-vaccination

Swine producers/end users — deploy vaccines to prevent disease outbreaks in breeding and grow-finish operations

Regulators/standards bodies — establish approval pathways, label claims, and residue safety thresholds for vaccine use

Recent Industry Insights

Analyst Overview

Table of Contents